Growing incidence rate of eye
inflammations or uveitis has driven the patients toward adopting effective
treatment options. In the coming years, majority of uveitis patients will be
seeking ocular inflammation treatments through combination therapies,
particularly due to collective effectiveness of therapeutics and prescribed
drugs. Leading pharma giant Allergan Plc. has recently cleared its Ozurdex
implant from FDA’s uveitis pipeline, and this new delivery system will mark a
key development for combination therapies in ocular inflammation treatment. In
addition to Allergan, Transparency Market Research also observes high stakes of
Novartis AG, Valeant Pharmaceuticals International, Inc., Abbvie, Inc., Alimera
Sciences, Inc., Eyegate Pharmaceuticals, Inc., pSivida Corporation, Pfizer,
Inc., Cipla Ltd., and Akorn, Inc. in the global ocular
inflammation treatment market over the coming years.
In its latest forecast study,
Transparency Market Research has profiled these companies has the key
stakeholders of global market for ocular inflammation treatments. Key
projections from the study assess the global ocular inflammation treatment to
touch a US$ 1 billion value by the end of 2026.
Regulatory stance of the FDA
towards clearing uveitis drugs from the pipelines is improving, and market players
are being favored to introduce novel administration techniques for ocular
inflammation treatments. During the period of assessment, 2017-2026, the global
market for ocular inflammation treatments is pegged to expand at a CAGR of 6.9%
in terms of value.
The report estimates that
incidence rate of uveitis in the US and Canada remains to be the highest. Over
the forecast period, North America will be observed as the world’s largest
ocular inflammation treatment marketplace. It is further estimated that treatment
of anterior uveitis will be predominant, considering it being the world’s most
common form of eye inflammation. By the end of 2026, more than US$ 530 million
worth of revenues are likely to be procured from treating anterior uveitis
across the globe.
Request for
Analysis of COVID19 Impact on Ocular Inflammation Treatment Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=41027
Topical Mode
of Administration to Reflect High Profits; Hospital Pharmacies to Showcase
Largest Distribution Channels for Uveitis Drugs
By 2026-end, oral mode of
administrating uveitis drugs will lose traction due to longer time course of
drug effect, while injectable administration will be least preferred for
triggering patient discomfort. Topical administration of ocular inflammation
drugs will translate highest share of revenues, and account for more than 50%
of global market value by the end of forecast period.
In 2018 and beyond, more than 42%
of revenues procured in the global ocular inflammation treatment market are
expected to be pulled in by hospital pharmacies. As the largest distribution
channel, majority of drugs on ocular inflammation treatments will be sold
through hospital pharmacies across the globe.
Buy now Ocular
Inflammation Treatment Market
Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=41027<ype=S
Nearly 30% of
Uveitis Patients to Prefer Corticosteroids for Ocular Inflammation Treatment
The report findings reveal a
growing demand for corticosteroids for treatment of ocular inflammations. In
2017, over US$ 150 million worth of corticosteroids were sold in the global
ocular inflammation treatment market. The effectiveness of corticosteroid eye
drops in treating uveitis by suppressing inflammations instantly will be
observed as a key driver for its growing demand in the coming years. Treating
ocular inflammations through administration of monoclonal antibodies is also
expected to witness surging demand, reflecting a high value CAGR of 8.1% over
the forecast period.
More Trending Reports by
Transparency Market Research:
About
Us
Transparency Market Research (TMR)
is a market intelligence company, providing global business information
reports and services. Our exclusive blend of quantitative forecasting and
trends analysis provides forward-looking insight for thousands of decision
makers. TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to gather, and
analyze information. Our business offerings represent the latest and the most
reliable information indispensable for businesses to sustain a competitive
edge.
Each TMR syndicated research
report covers a different sector - such as pharmaceuticals, chemicals, energy,
food & beverages, semiconductors, med-devices, consumer goods and
technology. These reports provide in-depth analysis and deep segmentation to
possible micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their overall
research requirement.
US
Office Contact
90
State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/
